BioCryst appoints Steve Frank to board; board size increased to 11

BIOCRYST PHARMACEUTICALS INC

Steven Frank elected to board effective May 2, 2025, filling new seat after board expansion from 10 to 11 directors.
Frank is chairman of global healthcare investment banking at J.P. Morgan; previously at Bear Stearns.
Initial equity grant of $500,000 (60% options, 40% RSUs), prorated from effective date to 2025 annual meeting.
Frank brings healthcare M&A and capital allocation expertise as BioCryst approaches profitability.
Frank's term expires at 2027 annual meeting; no committee assignments initially.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steven Frank

Director

BCRX · BIOCRYST PHARMACEUTICALS INC

Effective: 2025-05-02
Filed: May 1, 2025, 7:59 PM ET

On April 30, 2025, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) approved an increase in the size of the Board from ten to eleven directors and elected Steven Frank to fill the vacancy created by the enlargement of the Board, effective May 2, 2025 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Frank was elected as Director at BIOCRYST PHARMACEUTICALS INC.

Action: elected
Role: Director

Exact text from the filing

On April 30, 2025, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) approved an increase in the size of the Board from ten to eleven directors and elected Steven Frank to fill the vacancy created by the enlargement of the Board, effective May 2, 2025 (the “Effective Date”).

View on SEC.gov

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-25-002669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.